- Home
- D vs ARGX Comparison
D vs ARGX Comparison
Compare D & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- D
- ARGX
- Stock Information
- Founded
- D 1983
- ARGX 2008
- Country
- D United States
- ARGX Netherlands
- Employees
- D N/A
- ARGX N/A
- Industry
- D
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- D
- ARGX Health Care
- Exchange
- D Nasdaq
- ARGX Nasdaq
- Market Cap
- D 51.5B
- ARGX 46.3B
- IPO Year
- D N/A
- ARGX 2017
- Fundamental
- Price
- D $59.75
- ARGX $731.77
- Analyst Decision
- D Hold
- ARGX Strong Buy
- Analyst Count
- D 7
- ARGX 19
- Target Price
- D $59.57
- ARGX $777.83
- AVG Volume (30 Days)
- D 4.9M
- ARGX 373.6K
- Earning Date
- D 10-31-2025
- ARGX 10-30-2025
- Dividend Yield
- D 4.46%
- ARGX N/A
- EPS Growth
- D 86.34
- ARGX N/A
- EPS
- D 2.99
- ARGX 18.75
- Revenue
- D $15,227,000,000.00
- ARGX $3,120,821,000.00
- Revenue This Year
- D $11.04
- ARGX $80.01
- Revenue Next Year
- D $6.20
- ARGX $30.64
- P/E Ratio
- D $20.04
- ARGX $34.84
- Revenue Growth
- D 5.29
- ARGX 88.04
- 52 Week Low
- D $48.07
- ARGX $510.06
- 52 Week High
- D $62.46
- ARGX $779.03
- Technical
- Relative Strength Index (RSI)
- D 50.61
- ARGX 59.09
- Support Level
- D $59.36
- ARGX $745.91
- Resistance Level
- D $60.75
- ARGX $759.79
- Average True Range (ATR)
- D 0.94
- ARGX 16.15
- MACD
- D 0.01
- ARGX -4.28
- Stochastic Oscillator
- D 68.65
- ARGX 41.77
About D Dominion Energy Inc.
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion is constructing a rate-regulated 5.2 GW wind farm off the Virginia Beach coast.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.